• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Oct. 4, 2016

View Archived Issues

Allergan shells out $1.27B for Astrazeneca's IL-23 antibody in phase IIb for Crohn's disease

LONDON – It seems there is no stopping Allergan plc, which has signed its eighth sizeable deal in six months, paying $250 million of a potential $1.27 billion up front for a license to Astrazeneca plc's Medi2070, an IL-23 antibody in phase IIb development for Crohn's disease. Read More

Other news to note

Collegium Pharmaceutical Inc., of Canton, Mass., said it submitted a new drug submission to Health Canada to gain marketing approval for its abuse-deterrent opioid, Xtampza ER (oxycodone extended-release). Read More

In the clinic

Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Sanofi SA, of Paris, said detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled phase III studies evaluating Dupixent (dupilumab) in adult patients with inadequately controlled moderate to severe atopic dermatitis (AD), were published in The New England Journal of Medicine. Read More

Financings

Novabay Pharmaceuticals Inc., of Emeryville, Calif., said that during the third quarter it received $7 million from the early exercise of 3.67 million warrants issued as part of five previously completed financings. Read More

Carrick Therapeutics launches with $95M

DUBLIN – Carrick Therapeutics Ltd. raised an eye-catching $95 million in a series A funding and declared its ambition to become Europe's leading oncology company by pursuing a new approach to cancer therapy. Read More

VC investments up in third quarter; sign of the Moderna times

Investments in U.S. private biopharmaceutical companies tracked by BioWorld were up about 20 percent year over year in the third quarter, raising nearly $1.7 billion compared to about $1.4 billion in the year-ago quarter. Read More

Roivant's Myovant files for $173M IPO to fund phase III-ready asset

With Alzheimer's-focused spinout Axovant Sciences Ltd. currently holding the record for largest biopharma IPO – last year's $362 million raise – another Roivant Ltd.-launched firm is testing the public markets. Read More

Merrimack CEO resigns in major restructuring

Amid slower-than-anticipated sales of its second-line pancreatic cancer drug Onivyde (irinotecan liposome injection), Merrimack Pharmaceuticals Inc. president and CEO Robert Mulroy resigned and the company moved to cut 22 percent of its work force in a major restructuring it said would prioritize its R&D efforts and eliminate more than $200 million in expected costs over the next two years. Read More

Nobel Prize goes for autophagy research

"Basically, it's not easy to define what will serve humanity." So said Yoshinori Ohsumi, honorary professor at the Tokyo Institute of Technology, after winning the 2012 Kyoto Prize in Life Sciences for his research. Read More

Zai nabs China rights for Tesaro's PARP inhibitor in ovarian cancer

SHANGHAI – It's not often that Chinese biopharmas are able to nab China rights for a promising late-stage oncology candidate in global trials. But that's exactly what Shanghai-based Zai Labs Ltd. did when it obtained exclusive China rights for niraparib from Tesaro Inc. Read More

Looking 'Fab' in psoriasis: Cimzia scales trial ladder, scratches phase III itch #1

Psoriasis trial results "tend to vary a little bit" between experiments, Dermira Inc.'s chief development officer Luis Peña told BioWorld Today, but consistency of data in two yet-to-report phase III studies with Cimzia (certolizumab pegol) is "nothing we're concerned about." Read More

Regulatory front

While U.S. government-supported clinical trials of Zika vaccines are progressing, the damage caused by a delay in funding will continue to hurt other programs, Health and Human Services (HHS) Secretary Sylvia Burwell said Monday in a media call to discuss progress in the battle against the mosquito-borne virus. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe